CERE

Cerevel Therapeutics Holdings, Inc.

41.25 USD
-0.05 (-0.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cerevel Therapeutics Holdings, Inc. stock is down -1.81% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 12 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Jan 15:15 15 Mar, 2024 40.00 PUT 1998 1
26 Jan 17:23 16 Feb, 2024 30.00 CALL 20 83
26 Jan 19:50 16 Feb, 2024 20.00 CALL 20 99
06 Feb 17:05 20 Dec, 2024 40.00 CALL 100 3859
14 Feb 15:25 15 Mar, 2024 25.00 CALL 20 0
15 Feb 15:47 15 Mar, 2024 42.50 CALL 200 655
16 Feb 19:48 20 Dec, 2024 35.00 PUT 495 5641
20 Feb 14:51 20 Dec, 2024 35.00 CALL 36 1976
20 Feb 20:23 15 Mar, 2024 42.50 PUT 500 1194
22 Feb 15:16 19 Apr, 2024 40.00 CALL 851 1

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist, and CVL-871, which is in Phase 2a clinical trial to treat dementia-related apathy.